Jaguar Health Completes Private Placement Deal

Jaguar Health, Inc. (NASDAQ:JAGX) is among the best fundamentally strong penny stocks to buy right now. On September 9, 2025, Jaguar Health, Inc. (NASDAQ:JAGX) signed securities purchase agreements with some investors for the issuance and sale of nearly 951 shares of Series N Perpetual Preferred Stock. The funds from this $2.38 million private placement transaction will be allocated to working capital, general corporate purposes, and repayment of certain existing notes.

The year 2025 marked a pivotal year of convergence for Jaguar Health, Inc. (NASDAQ:JAGX). During its latest earnings call, management highlighted an intersection of clinical and regulatory catalysts that could prove transformative for the company. With a clear strategy to pursue business development partnerships for licensed rights, the company is committed to achieving the impossible.

Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month

What’s even more interesting is that Jaguar Health, Inc. (NASDAQ:JAGX) is now enhancing its product portfolio by supporting investigator-initiated trials in adult patients living with short bowel syndrome and intestinal failure. While patient treatment has already begun, results aren’t expected until 2026.

Jaguar Health, Inc. (NASDAQ:JAGX), headquartered in San Francisco, California, is a commercial-stage pharmaceuticals company specializing in plant-based prescription medicines for people and animals suffering from gastrointestinal distress. The company operates through two segments: Animal Health and Human Health.

While we acknowledge the potential of JAGX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JAGX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.